During the past decade, Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie" are "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie" in a lesser frequency.

Most popular intervention types in "Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Lenalidomide" (2 trials), "Isatuximab" (1 trials) and "elotuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".